← Back to Search

Antioxidant

Mito-MES for Coronavirus

Phase 2
Recruiting
Led By Theodoros Kelesidis, MD, PHD, Msc
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 14 days after exposure to sars-cov-2
Awards & highlights

Study Summary

"Participants without major health issues will be randomly assigned to take either Mito-MES or a placebo to see if it can help prevent COVID-19 after being in close contact with someone who has the

Who is the study for?
This trial is for adults aged 18-65 who've been exposed to COVID-19 without masks, are asymptomatic, and live with someone diagnosed with the virus. They must test negative for SARS-CoV-2 initially and not have major health issues including kidney or gastrointestinal diseases.Check my eligibility
What is being tested?
The study tests if Mitoquinone (Mito-MES), taken orally, can prevent COVID-19 after high-risk exposure compared to a placebo. Participants will be randomly assigned to either receive Mito-MES or a placebo in this prevention trial.See study design
What are the potential side effects?
Potential side effects of Mitoquinone/Mito-MES may include mild stomach upset or allergic reactions; however, it's being studied as a safe option so severe side effects are not expected.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 14 days after exposure to sars-cov-2
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 14 days after exposure to sars-cov-2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
SARS-CoV-2 infection
Secondary outcome measures
Duration of symptoms of SARS-CoV-2 infection
Safety of mito-MES
Severity of symptoms of SARS-CoV-2 infection
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Mito-MESExperimental Treatment1 Intervention
MitoQ pills 20 mg orally daily taken during the study and initiated within 3 days post exposure.
Group II: Control groupPlacebo Group1 Intervention
Placebo pills orally daily taken during the study and initiated within 3 days post exposure.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitoquinone/mitoquinol mesylate
2022
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,048 Previous Clinical Trials
1,053,623 Total Patients Enrolled
Theodoros Kelesidis, MD, PHD, MscPrincipal InvestigatorUT Southwestern Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any ongoing efforts to enroll patients in this clinical trial?

"Indeed, as per the details on clinicaltrials.gov, this trial is actively enrolling participants. The study was first listed on March 1, 2024, and last updated on March 7, 2024. A total of 112 individuals are sought for enrollment at a single site."

Answered by AI

Which specific criteria must individuals meet in order to qualify for participation in this research?

"The trial aims to recruit 112 individuals aged between 18 and 65 who have contracted COVID-19. Eligible participants must meet the subsequent conditions: Age range from 18 to 65 years Asymptomatic upon enrollment after potential viral exposure High-risk contact with a confirmed case of COVID-19 in an unmasked setting Living with at least one household member diagnosed with COVID-19 Negative SARS-CoV-2 test results at baseline."

Answered by AI

Is there an age threshold for participation in this medical study, specifically regarding individuals older than 25 years?

"For this trial, individuals must be at least 18 years old but not exceed 65 years in age to qualify for participation."

Answered by AI

Has the FDA granted approval for Mito-MES?

"With this being a Phase 2 trial lacking efficacy data but having some safety information, Mito-MES has been rated at 2 on the safety scale by our team at Power."

Answered by AI

What is the current number of individuals being admitted into this particular medical trial?

"Affirmative. The details available on clinicaltrials.gov indicate that this research endeavor is presently in search of individuals to partake. Initially shared on the 3rd of January 2024, with its latest update recorded on the 7th of March 2024, this investigation aims to recruit around 112 participants at a single site."

Answered by AI

Who else is applying?

What site did they apply to?
University of Texas Southwestern Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Theodoros Kelesidis 2024. "Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05886816.
All > Covid 19
~75 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top